摘要
目的 比较以门冬酰胺酶为基础方案与CHOP方案（环磷酰胺、阿霉素、长春新碱、泼尼松）化疗联合放疗一线治疗结外NK/T细胞淋巴瘤的近期疗效、远期生存及安全性.方法 181例初诊经影像学、病理学检查确诊为结外NK/T细胞淋巴瘤患者,其中69例接受CHOP方案化疗,112例接受以门冬酰胺酶为基础方案化疗,完成2个周期以上化疗后行侵犯野放射治疗.治疗结束后评价疗效.结果 CHOP组、含门冬酰胺酶组总有效率分别为72.5％和90.2％,差异有统计学意义（P=0.002）,两组1、2、5年总生存率分别为82.6％、61.9％、28.4％和96.0％、88.3％、65.1％,两组1、2、5年无进展生存率分别为63.8％、44.0％、21.0％和94.2％、79.8％、50.0％,差异有统计学意义（P=0.000）.两组患者的主要不良反应为骨髓抑制、胃肠道反应、感染、肝功能损害等,均未出现治疗中断及相关死亡.结论 与CHOP方案相比,以门冬酰胺酶为主的联合化疗结合放疗能够显著提高结外NK/T细胞淋巴瘤患者的疗效,并改善其远期生存,安全性好.
Objective To analyze the short-term efficacy,overall survival （OS）,and safety in newly diagnosed extranodal NK/T-cell lymphoma （ENKTL） patients with L-asparaginase based regimens or CHOP regimen in combination with radiotherapy as first-line treatment.Methods Of the total 181 patients diagnosed by imaging and pathology,69 patients received CHOP regimen and 112 patients received L-asparaginase based regimens.All the patients received radical radiotherapy （RT） after 6 cycles of chemotherapy.Results The overall response rates of L-asparaginase-based group and CHOP group were 90.2％ and 72.5％,respectively（P=0.002）.The 1,2,5-year OS and progression-free survival （PFS） in L-asparaginase-based group were 96.0％,88.3％,65.1％ and 94.2％,79.8％,50.0％,respectively.The 1,2,5-year OS and PFS in CHOP group were 82.6％,61.9％,28.4％ and 63.8％,44.0％,21.0％ （P=0.000）.Conclusions Compared with CHOP regimen,L-asparaginase-based chemotherapy is more effective and safe for newly diagnosed nasal-type ENKTL.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2014年第7期614-618,共5页
Chinese Journal of Hematology
基金
国家自然科学基金（81170520、81000921）
河南省卫生厅科研课题（2011010014）
关键词
淋巴瘤
结外NK-T细胞
抗肿瘤联合化疗方案
门冬酰胺酶
治疗结果
Lymphoma, extranodal NK-T-cell
Antineoplastic combined chemotherapy protocols
L-asparaginase
Treatment outcome
